Oppenheimer Starts Ambrx Biopharma (AMAM) at Outperform, 'Remarkable Turnaround Story'
Tweet Send to a Friend
(Updated - June 1, 2023 4:03 PM EDT)
Oppenheimer analyst Matthew Biegler initiates coverage on Ambrx Biopharma (NASDAQ: AMAM) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Oppenheimer analyst Matthew Biegler initiates coverage on Ambrx Biopharma (NASDAQ: AMAM) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
